Univest
Univest
  • Markets

Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Which Stock Should You Track

  • July 31, 2026
  • Posted by: Ankit Jaiswal
  • Category: News
No Comments
Sun Pharmaceutical Industries vs Dr Reddy's Laboratories: Which Stock Should You Track

Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: India’s largest pharmaceutical company by market cap vs a leading Indian pharmaceutical company with a diversified global generics and bios…

Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories is a comparison investors search for because the two companies represent genuinely different positions within Pharmaceuticals. This Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories breakdown goes beyond generic labels and looks at real numbers: reach, products, the latest results each company has declared, and how each stock is positioned today. Understanding Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories this way is more useful than a surface-level label, because it shows where each company actually stands rather than how it describes itself.

Table of Contents

Toggle
  • Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Reach and Market Position
  • Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Key Products and Business Mix
  • Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Latest Results
  • Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Stock and Valuation
  • Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Quick Comparison Table
  • Conclusion
  • Frequently Asked Questions
    • What is the main difference between Sun Pharmaceutical Industries and Dr Reddy’s Laboratories?
    • How do Sun Pharmaceutical Industries and Dr Reddy’s Laboratories’s latest results compare?
    • What sector do Sun Pharmaceutical Industries and Dr Reddy’s Laboratories operate in?
    • Should I invest in Sun Pharmaceutical Industries or Dr Reddy’s Laboratories?
    • What are the key products of Sun Pharmaceutical Industries?
    • What are the key products of Dr Reddy’s Laboratories?
    • How do Sun Pharmaceutical Industries and Dr Reddy’s Laboratories compare on market position?

Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Reach and Market Position

In the Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories comparison, Sun Pharmaceutical Industries stands out for India’s largest drugmaker by market cap, with a growing specialty pharmaceuticals franchise alongside its generics business. This scale gives Sun Pharmaceutical Industries a distinct position within Pharmaceuticals that shapes how it competes.

Click Here – Get Free Investment Predictions

Dr Reddy’s Laboratories, on the other hand, is built around a Hyderabad-based global pharmaceutical major with a diversified footprint across North America, Europe, Emerging Markets and India. Comparing Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories on reach alone shows two different growth strategies, not a single verdict.

Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Key Products and Business Mix

Sun Pharmaceutical Industries’s business runs on generic drugs, specialty pharmaceuticals (including the Ilumya brand), and active pharmaceutical ingredients. This product mix is central to any Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories comparison, since it explains where each company’s revenue actually comes from.

Dr Reddy’s Laboratories instead leans on generic drugs, biosimilars, active pharmaceutical ingredients, and branded formulations. The Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories product comparison shows these are genuinely different businesses, not just different brand names in the same category.

Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Latest Results

Looking at real numbers rather than claims, Sun Pharmaceutical Industries’s latest disclosed results show Q1 FY27 results were scheduled for July 31, 2026; analysts had projected around 11% topline growth with profit expected to decline 7-11% YoY on margin pressure from higher input costs. This is the clearest evidence available for the Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories comparison on Sun Pharmaceutical Industries’s side.

Dr Reddy’s Laboratories’s latest disclosed results show Q1 FY27 consolidated net profit of around Rs 1,290 crore, down about 8% YoY, on revenue of about Rs 7,650-8,071 crore, as North American generic sales faced pricing pressure on key molecules including lenalidomide; Emerging Markets revenue grew 31% YoY and India grew 17% YoY. Weighing Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories on actual results, rather than headline positioning, is what separates a useful comparison from a generic one.

Compare Sun Pharmaceutical Industries and Dr Reddy’s Laboratories Fundamentals on the Univest Screener

Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Stock and Valuation

On the market side, Sun Pharmaceutical Industries is described as: Market cap around Rs 4,32,036 crore. Dr Reddy’s Laboratories is described as: Shares touched a 52-week low following the Q1 FY27 results per market reports. The Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories valuation gap often reflects how the market is pricing each company’s growth and risk profile differently.

Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories: Quick Comparison Table

Parameter Sun Pharmaceutical Industries Dr Reddy’s Laboratories
Sector Pharmaceuticals Pharmaceuticals
Market position India’s largest pharmaceutical company by market cap a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint
Reach India’s largest drugmaker by market cap, with a growing specialty pharmaceuticals franchis a Hyderabad-based global pharmaceutical major with a diversified footprint across North Am
Latest results Q1 FY27 results were scheduled for July 31, 2026; analysts had projected around 11% topline growth w Q1 FY27 consolidated net profit of around Rs 1,290 crore, down about 8% YoY, on revenue of about Rs

Conclusion

Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories ultimately comes down to two companies solving similar problems in different ways. Sun Pharmaceutical Industries brings India’s largest pharmaceutical company by market cap, while Dr Reddy’s Laboratories brings a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint. Investors weighing Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories should track both companies’ upcoming results and valuation gap rather than picking a side on reputation alone. This Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories breakdown is a starting point, not a final verdict.

Download the Univest iOS App or Univest Android App to track Sun Pharmaceutical Industries and Dr Reddy’s Laboratories live price and get daily stock recommendations.

Disclaimer: Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

What is the main difference between Sun Pharmaceutical Industries and Dr Reddy’s Laboratories?

Ans. The main difference in the Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories comparison lies in scale and business mix. Sun Pharmaceutical Industries is built on India’s largest pharmaceutical company by market cap, while Dr Reddy’s Laboratories is positioned around a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint.

How do Sun Pharmaceutical Industries and Dr Reddy’s Laboratories’s latest results compare?

Ans. Comparing Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories on latest disclosed results: Sun Pharmaceutical Industries reported Q1 FY27 results were scheduled for July 31, 2026; analysts had projected around 11% topline growth with profit expected to decline 7-11% YoY, while Dr Reddy’s Laboratories reported Q1 FY27 consolidated net profit of around Rs 1,290 crore, down about 8% YoY, on revenue of about Rs 7,650-8,071 crore, as North American gen.

What sector do Sun Pharmaceutical Industries and Dr Reddy’s Laboratories operate in?

Ans. Sun Pharmaceutical Industries operates in Pharmaceuticals and Dr Reddy’s Laboratories operates in Pharmaceuticals. Even where the sectors overlap, the Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories comparison shows different product mixes and market positions.

Should I invest in Sun Pharmaceutical Industries or Dr Reddy’s Laboratories?

Ans. Both Sun Pharmaceutical Industries and Dr Reddy’s Laboratories have distinct strengths within their space. Investors comparing Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories should review the latest quarterly results, valuation and their own risk profile, and consult a financial advisor before deciding.

What are the key products of Sun Pharmaceutical Industries?

Ans. Sun Pharmaceutical Industries’s key products and business lines include generic drugs, specialty pharmaceuticals (including the Ilumya brand), and active pharmaceutical ingredients.

What are the key products of Dr Reddy’s Laboratories?

Ans. Dr Reddy’s Laboratories’s key products and business lines include generic drugs, biosimilars, active pharmaceutical ingredients, and branded formulations.

How do Sun Pharmaceutical Industries and Dr Reddy’s Laboratories compare on market position?

Ans. On market position, Sun Pharmaceutical Industries holds India’s largest pharmaceutical company by market cap, while Dr Reddy’s Laboratories holds a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint. The Sun Pharmaceutical Industries vs Dr Reddy’s Laboratories comparison shows both companies lead in different ways rather than one being universally ahead.



News
Author: Ankit Jaiswal
Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.

Leave a Reply Cancel reply